WASHINGTON , April 3 -- The office of Sen. Maggie Hassan , D- New Hampshire , issued the following news release:

* * *

- The Bipartisan Legislation Includes a Hassan-Backed Provision to Recoup Millions of Taxpayer Dollars from Big Pharma's Exploitive Tactics

* * *

Senator Maggie Hassan , a member of the Senate Health , Education, Labor, and Pensions (HELP) Committee, applauded the unanimous Senate passage yesterday of bipartisan legislation to help improve Medicaid, which includes a provision backed by Senator Hassan to close a loophole that allows the pharmaceutical industry to exploit taxpayers dollars. The bipartisan Medicaid Services Investment and Accountability Act of 2019 passed the House of Representatives last month and now heads to the President's desk for a signature.


The bipartisan Medicaid Services Investment and Accountability Act includes the Right Rebate Act, which Senator Hassan cosponsored. The Right Rebate Act will give Medicaid more tools to go after drug manufacturers that misclassify a drug as a generic when it should be a brand name. When a pharmaceutical company misclassifies a drug as a generic drug as part of the Medicaid Drug Rebate Program (MDRP), the company can pay less in rebates into the program and cheat taxpayers.

"This bipartisan bill will help hold pharmaceutical companies accountable and ensure that taxpayers dollars are used responsibly, and I urge President Trump to sign this commonsense legislation without delay," Senator Hassan said.